Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

74.57EUR
11:35am EDT
Change (% chg)

€0.57 (+0.77%)
Prev Close
€74.00
Open
€74.20
Day's High
€74.57
Day's Low
€73.62
Volume
2,253,113
Avg. Vol
2,388,566
52-wk High
€80.44
52-wk Low
€71.32

Latest Key Developments (Source: Significant Developments)

BIOCORP Enters Exclusive Negotiations With Sanofi
Wednesday, 3 Jul 2019 02:00am EDT 

July 3 (Reuters) - BIOCORP PRODUCTION SA ::BIOCORP ENTERS EXCLUSIVE NEGOTIATIONS WITH SANOFI TO USE THEIR MALLYATM CONNECTED DEVICE WITH SANOFI’S INTEGRATED DIABETES CARE PLATFORM.BIOCORP ENTERS EXCLUSIVE NEGOTIATIONS WITH SANOFI TO USE THEIR MALLYATM CONNECTED DEVICE WITH SANOFI’S INTEGRATED DIABETES CARE PLATFORM.BIOCORP TO RECEIVE UPFRONT PAYMENT OF 4 MEUR.UNDER TERMS OF THESE EXCLUSIVE NEGOTIATIONS, BIOCORP WILL GET AN INITIAL PAYMENT OF EUR 4 MILLION FROM SANOFI TO SUPPORT RELATED DEVELOPMENT ACTIVITIES.  Full Article

FDA Approves Dupixent (Dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis
Wednesday, 26 Jun 2019 01:29pm EDT 

June 26 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA APPROVES DUPIXENT® (DUPILUMAB) FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS.FDA APPROVED DUPIXENT (DUPILUMAB) FOR USE WITH OTHER MEDICINES TO TREAT CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS.  Full Article

Voyager Therapeutics Announces Restructured Gene Therapy Relationship With Sanofi Genzyme
Monday, 17 Jun 2019 07:30am EDT 

June 17 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES RESTRUCTURED GENE THERAPY RELATIONSHIP WITH SANOFI GENZYME AND PORTFOLIO UPDATE.VOYAGER THERAPEUTICS INC - GAINS WORLDWIDE RIGHTS TO VY-HTT01 FOR HUNTINGTON'S DISEASE.VOYAGER THERAPEUTICS INC - GAINS WORLDWIDE RIGHTS TO VY-HTT01 FOR HUNTINGTON'S DISEASE.VOYAGER THERAPEUTICS INC - RESOURCES TO BE REALLOCATED TO VY-HTT01 AND OTHER PROGRAMS; INTENDS TO SEEK A PARTNER FOR SOD1 ALS PROGRAM.VOYAGER THERAPEUTICS INC - RESOURCES TO BE REALLOCATED TO VY-HTT01 AND OTHER PROGRAMS; INTENDS TO SEEK A PARTNER FOR SOD1 ALS PROGRAM.VOYAGER THERAPEUTICS INC - NO LONGER EXPECTS TO FILE AN IND APPLICATION FOR VY-SOD102 IN 2019.VOYAGER THERAPEUTICS INC - IN CONSIDERATION OF RIGHTS RETURNED, VOYAGER HAS AGREED TO MAKE A $10 MILLION UPFRONT PAYMENT TO SANOFI GENZYME.VOYAGER THERAPEUTICS INC - SANOFI GENZYME OBTAINS EXCLUSIVE OPTION RIGHTS TO SELECT NOVEL AAV CAPSIDS OWNED OR CONTROLLED BY VOYAGER FOR EXCLUSIVE USE.VOYAGER THERAPEUTICS INC - AN ADDITIONAL $10 MILLION MILESTONE PAYMENT IS DUE TO SANOFI GENZYME.VOYAGER THERAPEUTICS INC - PRECLINICAL STUDIES ARE UNDERWAY WITH VY-HTT01.VOYAGER - SANOFI GENZYME'S OPTION TO ACQUIRE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO A FUTURE VOYAGER CNS ORPHAN PROGRAM IS TERMINATED.VOYAGER THERAPEUTICS INC - VOYAGER INTENDS TO SEEK A PARTNER TO ADVANCE ITS PRECLINICAL PROGRAM FOR SOD1 ALS.VOYAGER THERAPEUTICS INC - VOYAGER NO LONGER EXPECTS TO FILE AN IND APPLICATION FOR VY-SOD102 IN 2019.  Full Article

Regeneron Announces Positive Early-Stage Data For REGN1979 In Patients With B-Cell Non-Hodgkin Lymphoma
Friday, 14 Jun 2019 07:00am EDT 

June 14 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON CD20XCD3 BISPECIFIC REGN1979 SHOWS POSITIVE RESULTS IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, INCLUDING IN CAR-T FAILURES.REGENERON PHARMACEUTICALS - IN THIS TRIAL, TWO PATIENTS WHO FAILED CAR-T THERAPY AND RECEIVED REGN1979 80 MG ACHIEVED COMPLETE RESPONSES.REGENERON PHARMACEUTICALS - 93% OVERALL RESPONSE & 71% COMPLETE RESPONSE RATES IN FOLLICULAR LYMPHOMA GRADES 1 TO 3A TREATED WITH REGN1979 5 MG-320 MG.  Full Article

Verily Forms Strategic Alliances With Novartis, Otsuka, Pfizer And Sanofi To Transform Clinical Research
Tuesday, 21 May 2019 08:00am EDT 

May 21 (Reuters) - Verily, Novartis, Otsuka, Pfizer And Sanofi::VERILY FORMS STRATEGIC ALLIANCES WITH NOVARTIS, OTSUKA, PFIZER AND SANOFI TO TRANSFORM CLINICAL RESEARCH.VERILY FORMS STRATEGIC ALLIANCES WITH NOVARTIS, OTSUKA, PFIZER AND SANOFI TO TRANSFORM CLINICAL RESEARCH.VERILY - BIOPHARMACEUTICAL ORGANIZATIONS JOIN PROJECT BASELINE INITIATIVE TO ENGAGE MORE PATIENTS AND CLINICIANS IN RESEARCH.  Full Article

Regeneron Announces Updated Libtayo Results In Advanced Cutaneous Squamous Cell Carcinoma
Thursday, 16 May 2019 07:00am EDT 

May 16 (Reuters) - Regeneron Pharmaceuticals Inc ::UPDATED LIBTAYO® (CEMIPLIMAB-RWLC) RESULTS REINFORCE DURABLE AND SUBSTANTIAL RESPONSE RATES IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.REGENERON PHARMACEUTICALS INC - NEW DATA AT ASCO INCLUDE MORE THAN DOUBLE PATIENTS PREVIOUSLY REPORTED.REGENERON PHARMACEUTICALS INC - MEDIAN OVERALL SURVIVAL STILL NOT REACHED WITH A MEDIAN FOLLOW-UP OF UP TO 17 MONTHS IN STUDY.  Full Article

FDA Says Approval Of Dengvaxia Was Granted To Sanofi Pasteur
Wednesday, 1 May 2019 06:35pm EDT 

May 1 (Reuters) - U.S. FDA::FIRST FDA-APPROVED VACCINE FOR PREVENTION OF DENGUE DISEASE IN ENDEMIC REGIONS.FDA - APPROVAL OF DENGVAXIA WAS GRANTED TO SANOFI PASTEUR.FDA - APPROVAL OF DENGVAXIA, FOR PEOPLE AGED 9 THROUGH 16.  Full Article

Regeneron Says FDA Approves Praluent To Prevent Heart Attack, Stroke And Unstable Angina Requiring Hospitalization
Friday, 26 Apr 2019 07:19pm EDT 

April 26 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA APPROVES PRALUENT® (ALIROCUMAB) TO PREVENT HEART ATTACK, STROKE AND UNSTABLE ANGINA REQUIRING HOSPITALIZATION.REGENERON PHARMACEUTICALS INC SAYS FDA ALSO APPROVED PRALUENT AS AN ADJUNCT TO DIET, ALONE OR IN COMBINATION WITH OTHER LIPID-LOWERING THERAPIES.  Full Article

ZynquistaTM Now Approved In The EU For Treatment Of Adults With Type 1 Diabetes
Friday, 26 Apr 2019 04:01pm EDT 

April 26 (Reuters) - Sanofi SA ::ZYNQUISTATM NOW APPROVED IN THE EUROPEAN UNION FOR TREATMENT OF ADULTS WITH TYPE 1 DIABETES.SANOFI - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR ZYNQUISTA (SOTAGLIFLOZIN), DEVELOPED BY CO AND LEXICON.  Full Article

Sanofi: CHMP Issues Positive Opinion For Libtayo In Advanced Cutaneous Squamous Cell Carcinoma
Friday, 26 Apr 2019 11:15am EDT 

April 26 (Reuters) - SANOFI SA ::REG-CHMP ISSUES POSITIVE OPINION FOR LIBTAYO® (CEMIPLIMAB) IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.  Full Article

Photo

Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources

FRANKFURT/LONDON Bayer has approached U.S. drug firm Elanco Animal Health to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.